Bright Minds Biosciences
DRUG
47 hedge funds and large institutions have $137M invested in Bright Minds Biosciences in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 9 closing their positions.
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
38% more funds holding
Funds holding: 34 → 47 (+13)
0.23% more ownership
Funds ownership: 74.11% → 74.34% (+0.23%)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
27% less capital invested
Capital invested by funds: $188M → $137M (-$51.4M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.27M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.72M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$1.03M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$959K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$768K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.45M |
| 2 |
Millennium Management
New York
|
-$2.43M |
| 3 |
Walleye Capital
New York
|
-$947K |
| 4 |
Goldman Sachs
New York
|
-$802K |
| 5 |
PA
Perceptive Advisors
New York
|
-$718K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OAC
51
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$505K | -14,000 | Closed |
|
|
HF
52
HRT Financial
New York
| – | -$489K | -13,568 | Closed |
|
53
Citadel Advisors
Miami,
Florida
| – | -$248K | -6,885 | Closed |
|
54
Jane Street
New York
| – | -$238K | -6,600 | Closed |
|
|
UOC
55
UBS O'Connor
Chicago,
Illinois
| – | -$215K | -5,963 | Closed |
|
|
CIAM
56
Caitong International Asset Management
Hong Kong
| – | -$5.05K | -140 | Closed |
|
DRUG Hedge Fund Activity: Q2 2025 in Review
47 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q2 2025, worth a combined $137M — down 27% from $188M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new DRUG positions and 9 closed out — a net gain of 13 holders — while 7 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $6.27M. The largest seller was RA Capital Management, exiting entirely with an estimated $7.45M sold.
- 47 institutional investors held Bright Minds Biosciences (DRUG) as of Q2 2025, up from 34 in Q1 2025.
- Funds reported $137M of Bright Minds Biosciences stock for Q2 2025, down 27% quarter-over-quarter.
- 22 funds opened new Bright Minds Biosciences positions in Q2 2025 and 9 closed out, a net change of +13 holders.
- The largest Bright Minds Biosciences buyer in Q2 2025 was BlackRock, an estimated $6.27M added.
- The largest Bright Minds Biosciences seller in Q2 2025 was RA Capital Management, an estimated $7.45M sold.
Based on aggregated 13F filings for Q2 2025.